{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:57:20Z","timestamp":1794218240924,"version":"4.8.0"},"reference-count":143,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Severe asthma is \u201casthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and\/or systemic corticosteroids) to prevent it from becoming \u2018uncontrolled\u2019 or which remains \u2018uncontrolled\u2019 despite this therapy.\u201d The state of control was defined by symptoms, exacerbations and the degree of airflow obstruction. Therefore, for the diagnosis of severe asthma, it is important to have evidence for a diagnosis of asthma with an assessment of its severity, followed by a review of comorbidities, risk factors, triggers and an assessment of whether treatment is commensurate with severity, whether the prescribed treatments have been adhered to and whether inhaled therapy has been properly administered. Phenotyping of severe asthma has been introduced with the definition of a severe eosinophilic asthma phenotype characterized by recurrent exacerbations despite being on high dose ICS and sometimes oral corticosteroids, with a high blood eosinophil count and a raised level of nitric oxide in exhaled breath. This phenotype has been associated with a Type-2 (T2) inflammatory profile with expression of interleukin (IL)-4, IL-5, and IL-13. Molecular phenotyping has also revealed non-T2 inflammatory phenotypes such as Type-1 or Type-17 driven phenotypes. Antibody treatments targeted at the T2 targets such as anti-IL5, anti-IL5R\u03b1, and anti-IL4R\u03b1 antibodies are now available for treating severe eosinophilic asthma, in addition to anti-immunoglobulin E antibody for severe allergic asthma. No targeted treatments are currently available for non-T2 inflammatory phenotypes. Long-term azithromycin and bronchial thermoplasty may be considered. The future lies with molecular phenotyping of the airway inflammatory process to refine asthma endotypes for precision medicine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001990","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T22:00:13Z","timestamp":1653775213000},"page":"1141-1155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":93,"title":["Characteristics, phenotypes, mechanisms and management of severe asthma"],"prefix":"10.1097","volume":"135","author":[{"given":"Kian Fan","family":"Chung","sequence":"first","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK"},{"name":"Royal Brompton & Harefield NHS Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Dixey","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK"},{"name":"Royal Brompton & Harefield NHS Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Abubakar-Waziri","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK"},{"name":"Royal Brompton & Harefield NHS Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Bhavsar","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK"},{"name":"Royal Brompton & Harefield NHS Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujan H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Royal Brompton & Harefield NHS Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong 518053, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong 518053, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(19)31147-X","article-title":"Prevalence, risk factors, and management of asthma in China: a national cross-sectional study","volume":"394","author":"Huang","year":"2019","journal-title":"Lancet"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/cea.13378","article-title":"Severe asthma - a population study perspective","volume":"49","author":"Backman","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"R4-20250603","first-page":"917","article-title":"A crosssection study of severe asthma in eight provinces of China (in Chinese)","volume":"55","author":"Su","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R5-20250603","first-page":"1106","article-title":"A survey on clinical characteristics and risk factors of severe asthma in China (in Chinese)","volume":"100","author":"Wang","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.21037\/jtd.2017.04.74","article-title":"Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network","volume":"9","author":"Wang","year":"2017","journal-title":"J Thorac Dis"},{"key":"R7-20250603","first-page":"298","article-title":"Mortality and death cause proportion of respiratory disease in China, 2004-2005 (in Chinese)","volume":"44","author":"Li","year":"2010","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000338998","article-title":"The cost of persistent asthma in Europe: an international population-based study in adults","volume":"160","author":"Accordini","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/all.13771","article-title":"Precision medicine for the discovery of treatable mechanisms in severe asthma","volume":"74","author":"Chung","year":"2019","journal-title":"Allergy"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jaci.2010.07.019","article-title":"Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma","volume":"126","author":"Bousquet","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0037-1607391","article-title":"Diagnosis and management of severe asthma","volume":"39","author":"Chung","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/all.13629","article-title":"Treatable traits in the European U-BIOPRED adult asthma cohorts","volume":"74","author":"Simpson","year":"2019","journal-title":"Allergy"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaip.2016.12.030","article-title":"A structured approach to specialist-referred difficult asthma patients improves control of comorbidities and enhances asthma outcomes","volume":"5","author":"Tay","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1378\/chest.14-3056","article-title":"Dedicated severe asthma services improve health-care use and quality of life","volume":"148","author":"Gibeon","year":"2015","journal-title":"Chest"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17476348.2013.842129","article-title":"Non-adherence in difficult asthma and advances in detection","volume":"7","author":"Lindsay","year":"2013","journal-title":"Expert Rev Respir Med"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1183\/09031936.03.00017003","article-title":"Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treat asthma","volume":"22","author":"Robinson","year":"2003","journal-title":"Eur Respir J"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.200902-0166OC","article-title":"The prevalence of nonadherence in difficult asthma","volume":"180","author":"Gamble","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1183\/09031936.03.00017003","article-title":"Systematic assessment of difficult-to-treat asthma","volume":"22","author":"Robinson","year":"2003","journal-title":"Eur Respir J"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1378\/chest.130.1_suppl.65S","article-title":"Compliance, adherence, and concordance: implications for asthma treatment","volume":"130","author":"Horne","year":"2006","journal-title":"Chest"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2010.11.015","article-title":"Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health\/National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"127","author":"Fitzpatrick","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/rccm.200607-909OC","article-title":"IL4R alpha mutations are associated with asthma exacerbations and mast cell\/IgE expression","volume":"175","author":"Wenzel","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2009.07.035","article-title":"Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study","volume":"124","author":"Haselkorn","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"AmJ Respir Crit Care Med"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","article-title":"Factors associated with persistent airflow limitation in severe asthma","volume":"164","author":"ten Brinke","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1067\/mai.2001.113047","article-title":"Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection","volume":"107","author":"ten Brinke","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.jaci.2011.03.036","article-title":"Obesity and asthma: an association modified by age of asthma onset","volume":"127","author":"Holguin","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2011.06.009","article-title":"Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation","volume":"128","author":"Dixon","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e18574","DOI":"10.1371\/journal.pone.0018574","article-title":"Detrimental effects of environmental tobacco smoke in relation to asthma severity","volume":"6","author":"Comhair","year":"2011","journal-title":"PloS One"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1164\/rccm.200510-1589OC","article-title":"Effects of smoking cessation on lung function and airway inflammation in smokers with asthma","volume":"174","author":"Chaudhuri","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1183\/09031936.06.00077205","article-title":"Influence of body mass index on the response to asthma controller agents","volume":"27","author":"Peters-Golden","year":"2006","journal-title":"Eur Respir J"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.200511-1746OC","article-title":"Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma","volume":"175","author":"Lazarus","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.08.005","article-title":"Air pollution and resistance to inhaled glucocorticoids: evidence, mechanisms and gaps to fill","volume":"194","author":"Rider","year":"2019","journal-title":"Pharmacol Ther"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur Respir J"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/09031936.06.00074705","article-title":"The link between fungi and severe asthma: a summary of the evidence","volume":"27","author":"Denning","year":"2006","journal-title":"Eur Respir J"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4168\/aair.2019.11.6.763","article-title":"Future risks in patients with severe asthma","volume":"11","author":"Song","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/resp.13389","article-title":"Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Physical activity associates with disease characteristics of severe asthma, bronchiectasis and COPD","volume":"24","author":"McDonald","year":"2019","journal-title":"Respirology"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.alit.2017.02.013","article-title":"Predicting future risk of exacerbations in Japanese patients with adult asthma: a prospective 1-year follow up study","volume":"66","author":"Tanaka","year":"2017","journal-title":"Allergol Int"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2018.06.007","article-title":"Development and validation of personalized prediction to estimate future risk of severe exacerbations and uncontrolled asthma in patients with asthma, using clinical parameters and early treatment response","volume":"7","author":"Boer","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/thoraxjnl-2015-208138","article-title":"Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model","volume":"71","author":"Loymans","year":"2016","journal-title":"Thorax"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1164\/rccm.201808-1516OC","article-title":"Exacerbation patterns in adults with asthma in England. A population-based study","volume":"199","author":"Bloom","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.rmed.2012.11.014","article-title":"Natural history and risk factors of obstructive changes over a 10-year period in severe asthma","volume":"107","author":"Matsunaga","year":"2013","journal-title":"Respir Med"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1590\/S1806-37132014000400003","article-title":"Risk factors for death in patients with severe asthma","volume":"40","author":"Fernandes","year":"2014","journal-title":"J Bras Pneumol"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1378\/chest.08-0049","article-title":"A multivariate analysis of risk factors for the airtrapping asthmatic phenotype as measured by quantitative CT analysis","volume":"135","author":"Busacker","year":"2009","journal-title":"Chest"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/jcp.13.1.27","article-title":"The pathology of asthma, with special reference to changes in the bronchial mucosa","volume":"13","author":"Dunnill","year":"1960","journal-title":"J Clin Pathol"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepoli-zumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1378\/chest.12-0872","article-title":"Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI","volume":"143","author":"Gibeon","year":"2013","journal-title":"Chest"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","article-title":"Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A Delphi study","volume":"203","author":"Suehs","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/joim.12382","article-title":"Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies","volume":"279","author":"Chung","year":"2016","journal-title":"J Intern Med"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","article-title":"U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics","volume":"139","author":"Lefaudeux","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"1700634","DOI":"10.1183\/13993003.00634-2017","article-title":"Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2737","article-title":"The airway epithelium in asthma","volume":"18","author":"Lambrecht","year":"2012","journal-title":"Nat Med"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.alit.2017.08.011","article-title":"Role of airway epithelial barrier dysfunction in pathogenesis of asthma","volume":"67","author":"Gon","year":"2018","journal-title":"Allergol Int"},{"key":"R62-20250603","first-page":"6935","article-title":"Role of epithelial chemokines in the pathogenesis of airway inflammation in asthma (Review)","volume":"17","author":"Liu","year":"2018","journal-title":"Mol Med Rep"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Prefontaine","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lympho-poietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41590-018-0067-5","article-title":"Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33","volume":"19","author":"Cayrol","year":"2018","journal-title":"Nat Immunol"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1084\/jem.20112691","article-title":"Interleukin-1a controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33","volume":"209","author":"Willart","year":"2012","journal-title":"J Exp Med"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/all.13462","article-title":"Aryl hydrocarbon receptor activation by diesel exhaust particles mediates epithelium-derived cytokines expression in severe allergic asthma","volume":"73","author":"Weng","year":"2018","journal-title":"Allergy"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1172\/JCI126402","article-title":"Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling","volume":"129","author":"Altman","year":"2019","journal-title":"J Clin Invest"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2017.02.045","article-title":"Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma","volume":"141","author":"Rossios","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"1602135","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"1800938","DOI":"10.1183\/13993003.00938-2018","article-title":"T2-high\u201d in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin","volume":"53","author":"Pavlidis","year":"2019","journal-title":"Eur Respir J"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaci.2013.07.036","article-title":"Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma","volume":"133","author":"Peters","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1164\/ajrccm\/138.6_Pt_2.S54","article-title":"Epithelial injury by human eosinophils","volume":"138","author":"Venge","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.201512-2452OC","article-title":"A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED","volume":"195","author":"Kuo","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1165\/ajrcmb.14.4.8600935","article-title":"T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma","volume":"14","author":"Krug","year":"1996","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1046\/j.1365-2222.2003.01762.x","article-title":"Assessment of T lymphocyte cytokine production in induced sputum from asthmatics: a flow cytometry study","volume":"33","author":"Boniface","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/rccm.200310-1416OC","article-title":"Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma","volume":"171","author":"Cho","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1172\/JCI80911","article-title":"High IFN-g and low SLPI mark severe asthma in mice and humans","volume":"125","author":"Raundhal","year":"2015","journal-title":"J Clin Invest"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.0903162","article-title":"IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation","volume":"184","author":"Roussel","year":"2010","journal-title":"J Immunol"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.12-0598","article-title":"T helper 17 cells in airway diseases: from laboratory bench to bedside","volume":"143","author":"Halwani","year":"2013","journal-title":"Chest"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2009.02.024","article-title":"T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma","volume":"123","author":"Al-Ramli","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaci.2019.03.027","article-title":"IL-17-high asthma with features of a psoriasis immunophenotype","volume":"144","author":"\u00d6stling","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaci.2018.05.026","article-title":"Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation","volume":"143","author":"Jevnikar","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1365-2222.2009.03319.x","article-title":"Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma","volume":"39","author":"Macedo","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1164\/ajrccm.160.5.9806170","article-title":"Neutrophilic inflammation in severe persistent asthma","volume":"160","author":"Jatakanon","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jaci.2013.10.011","article-title":"Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis","volume":"133","author":"Moore","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0091-6749(95)70128-1","article-title":"Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation","volume":"95","author":"Fahy","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jaip.2018.02.012","article-title":"Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation","volume":"6","author":"Qiu","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1183\/09031936.00105013","article-title":"Elevated expression of the NLRP3 inflammasome in neutrophilic asthma","volume":"43","author":"Simpson","year":"2014","journal-title":"Eur Respir J"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rmed.2004.06.007","article-title":"Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma","volume":"99","author":"Nguyen","year":"2005","journal-title":"Respir Med"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1164\/rccm.200607-1062OC","article-title":"Epithelial cell proliferation contributes to airway remodeling in severe asthma","volume":"176","author":"Cohen","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1183\/09031936.00181608","article-title":"Airway smooth muscle thickness in asthma is related to severity but not duration of asthma","volume":"34","author":"James","year":"2009","journal-title":"Eur Respir J"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2009.03.049","article-title":"Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction","volume":"124","author":"Kaminska","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaci.2008.10.048","article-title":"Fibrocyte localization to the airway smooth muscle is a feature of asthma","volume":"123","author":"Saunders","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200710-1557OC","article-title":"Increased circulating fibrocytes in asthma with chronic airflow obstruction","volume":"178","author":"Wang","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2014.10.031","article-title":"Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma","volume":"135","author":"Lo","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaci.2007.01.055","article-title":"Specificity of basement membrane thickening in severe asthma","volume":"119","author":"Bourdin","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2004.09.034","article-title":"Increased TGF-beta2 in severe asthma with eosinophilia","volume":"115","author":"Balzar","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"L245","DOI":"10.1152\/ajplung.00068.2007","article-title":"Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-beta","volume":"293","author":"Xie","year":"2007","journal-title":"AmJ Physiol Lung Cell Mol Physiol"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/all.13727","article-title":"Contribution of airway eosinophils in airway wall remodeling in asthma: role of MMP-10 and MET","volume":"74","author":"Kuo","year":"2019","journal-title":"Allergy"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1164\/ajrccm.153.1.8542102","article-title":"Computed tomography of the lungs in asthma: influence of disease severity and etiology","volume":"153","author":"Paganin","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0033-8389(22)00406-7","article-title":"High-resolution computed tomography of obstructive lung disease","volume":"32","author":"Webb","year":"1994","journal-title":"Radiol Clin North Am"},{"key":"R105-20250603","first-page":"782","article-title":"\u201cDensity mask\u201d. An objective method to quantitate emphysema using computed tomography","volume":"94","author":"Muller","year":"1988","journal-title":"Chest"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.09-0174","article-title":"Qualitative analysis of high-resolution CT scans in severe asthma","volume":"136","author":"Gupta","year":"2009","journal-title":"Chest"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1445-5994.2010.02192.x","article-title":"Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology","volume":"40","author":"Hew","year":"2010","journal-title":"Intern Med J"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2004.07.065","article-title":"Oral corticosteroids in poorly controlled asthma","volume":"115","author":"Colice","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201304-0775OC","article-title":"The effects of airway microbiome on corticosteroid responsiveness in asthma","volume":"188","author":"Goleva","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.181.6.4089","article-title":"TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice","volume":"181","author":"McKinley","year":"2008","journal-title":"J Immunol"},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J Exp Med"},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2222.2005.02314.x","article-title":"The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma","volume":"35","author":"Berry","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S2213-2600(21)00170-3","article-title":"Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma","volume":"9","author":"Chung","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(13)70128-0","article-title":"New treatments for severe treatment-resistant asthma: targeting the right patient","volume":"1","author":"Chung","year":"2013","journal-title":"Lancet Respir Med"},{"key":"R123-20250603","first-page":"CD009019","article-title":"Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children","volume":"12","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N Engl J Med"},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","article-title":"Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma","volume":"395","author":"Peters","year":"2020","journal-title":"Lancet"},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"156e1","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.chest.2020.11.060","article-title":"Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice","volume":"159","author":"Wechsler","year":"2021","journal-title":"Chest"},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaci.2016.08.009","article-title":"Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations","volume":"139","author":"Pretolani","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"1700017","DOI":"10.1183\/13993003.00017-2017","article-title":"Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies","volume":"50","author":"Chupp","year":"2017","journal-title":"Eur Respir J"},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/02770903.2016.1263652","article-title":"Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics","volume":"54","author":"Burn","year":"2017","journal-title":"J Asthma"},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","article-title":"Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials","volume":"9","author":"Chaudhuri","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaci.2017.02.004","article-title":"Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment?","volume":"139","author":"Chung","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:07:55Z","timestamp":1748977675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":143,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001990","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}